Bruton tyrosine kinase inhibitors at the time of cardio-oncology: proving safety on right ventricular function and afterload

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Observational analysis shows BTKIs do not affect right ventricular function in patients with CLL, suggesting safety in therapy.

BTKIs do not modify pulmonary artery pressures or right ventricular function over 6 months.
Nearly all echocardiographic right ventricular parameters remained stable, indicating no significant impact of BTKIs.
The study analyzed 30 patients, with initial and follow-up echocardiograms demonstrating no evidence of dysfunction.
A slight reduction in global longitudinal strain was noted, warranting further investigation with larger cohorts.

Iervolino et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark